Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioDynamics
Oxford BioDynamics
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Pharmaceutical
Oxford BioDynamics appoints professor to its Scientific Advisory Board
Professor Iain McInnes will apply his expertise and insight as the company’s EpiSwitch technology continues to be adopted
Pharmaceutical
Oxford BioDynamics appoints new President for US subsidiary
Glen Ferguson has been made Senior VP of US at the parent company, but has also been appointed as the President of the new US subsidiary
Finance
Oxford BioDynamics signs fifth collaboration agreement in immuno-oncology space
The company will use its EpiSwitch platform to offer high resolution mapping of epigenetic profiles in patients
Pharmaceutical
Grant announcement of Canadian patent by Oxford BioDynamics
The now patented technology platform, EpiSwitch, enables the high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures
Research & Development
OBD presents latest data on the use of EpiSwitch
EpiSwitch biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1
Research & Development
Collaboration identifies tool to predict response to rheumatoid arthritis therapy
Study published in Journal of <i>Translational Medicine</i> demonstrates predictive power of EpiSwitch to identify inadequate response to methotrexate in early rheumatoid arthritis
Pharmaceutical
Oxford BioDynamics appoint Paul Stockdale CFO
Subscribe now